Equities Analysts Issue Forecasts for Amgen FY2026 Earnings

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at Erste Group Bank upped their FY2026 earnings per share (EPS) estimates for Amgen in a report issued on Wednesday, February 18th. Erste Group Bank analyst H. Engel now expects that the medical research company will earn $22.36 per share for the year, up from their previous forecast of $22.28. Erste Group Bank currently has a “Buy” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period in the previous year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS.

A number of other research firms have also weighed in on AMGN. Leerink Partners raised their price target on shares of Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. Argus upped their price objective on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Sanford C. Bernstein lowered Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price on the stock. in a research report on Tuesday, January 20th. Guggenheim boosted their price target on Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Finally, Rothschild & Co Redburn raised their price objective on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $351.76.

Amgen Trading Down 0.2%

AMGN opened at $374.75 on Monday. The firm’s 50 day moving average is $343.21 and its 200-day moving average is $316.54. Amgen has a 52-week low of $261.43 and a 52-week high of $385.12. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm has a market capitalization of $202.02 billion, a P/E ratio of 26.34, a P/E/G ratio of 3.71 and a beta of 0.46.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen’s payout ratio is currently 70.84%.

Institutional Trading of Amgen

A number of hedge funds and other institutional investors have recently bought and sold shares of AMGN. Anfield Capital Management LLC increased its position in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares in the last quarter. Dogwood Wealth Management LLC increased its holdings in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Amgen in the fourth quarter worth approximately $26,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen in the second quarter worth approximately $27,000. Finally, Evelyn Partners Investment Management LLP bought a new position in shares of Amgen in the second quarter valued at approximately $32,000. Institutional investors own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Rothschild & Co Redburn says Amgen’s stock price is expected to rise — a bullish analyst view that could support upside if reiterated or joined by others. Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Rothschild & Co Redburn Analyst Says
• Neutral Sentiment: Amgen priced $4.0 billion of senior unsecured notes across multiple maturities — this increases debt but provides liquidity; impact depends on use of proceeds (buybacks, M&A, refinancing). Investors should watch tenor and coupon details to assess financing cost and leverage effects. Amgen Prices $4 Billion Senior Unsecured Notes Offering
• Neutral Sentiment: Amgen has been a “trending” ticker on sites like Zacks and Yahoo — heightened attention can lift liquidity and volatility but is not a directional fundamental catalyst by itself. Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: “Here’s What the Street is Saying” roundups summarize mixed analyst commentary — useful for context but check individual firm views for conviction and PTs. Here’s What the Street is Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Short-interest data reported for mid-February appears to show 0 shares (NaN/incomplete) and a 0.0 days-to-cover metric — likely a reporting glitch; no reliable evidence here of a significant short squeeze or increase in bearish positioning.
• Negative Sentiment: Barclays initiated coverage with an “equal-weight” rating and a $350 price target, implying roughly a mid-single-digit downside from recent levels — this new coverage (and PT below the current price) is a near-term headwind for sentiment. Barclays initiates coverage of Amgen (AMGN) with equal-weight recommendation

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.